Profusa, Inc. (PFSA)
NASDAQ: PFSA · Real-Time Price · USD
1.060
+0.069 (6.96%)
At close: Jul 30, 2026, 4:00 PM EDT
1.070
+0.010 (0.94%)
After-hours: Jul 30, 2026, 7:56 PM EDT
Company Description
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States.
It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.
Profusa, Inc. is based in Berkeley, California.
Profusa, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Jack Stover |
Contact Details
Address: 626 Bancroft Way, Suite A Berkeley, California 94710 United States | |
| Phone | 925 997 6925 |
| Website | profusa.com |
Stock Details
| Ticker Symbol | PFSA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859807 |
| CUSIP Number | 74319X306 |
| ISIN Number | US74319X3061 |
| Employer ID | 86-3437271 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Fred S. Knechtel | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 27, 2026 | 8-K | Current Report |
| Jul 7, 2026 | 424B3 | Prospectus |
| Jul 7, 2026 | 424B3 | Prospectus |
| Jul 7, 2026 | 424B3 | Prospectus |
| Jul 7, 2026 | 424B3 | Prospectus |
| Jul 7, 2026 | 424B3 | Prospectus |
| Jul 6, 2026 | 8-K | Current Report |
| Jun 23, 2026 | 8-K | Current Report |
| Jun 8, 2026 | 424B3 | Prospectus |
| Jun 8, 2026 | 8-K | Current Report |